We are live on ! Find out more
GBT

Global Blood Therapeutics, Inc.
GBT

Delisted

GBT was delisted on the 4th of October, 2022.

Back to rankings

134 hedge funds and large institutions have $1.03B invested in Global Blood Therapeutics, Inc. in 2017 Q2 according to their latest regulatory filings, with 37 funds opening new positions, 64 increasing their positions, 25 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

156% more repeat investments, than reductions

Existing positions increased: 64 | Existing positions reduced: 25

106% more first-time investments, than exits

New positions opened: 37 | Existing positions closed: 18

51% more call options, than puts

Call options by funds: $14M | Put options by funds: $9.27M

16% more funds holding

Funds holding: 116 → 134 (+18)

11% less capital invested

Capital invested by funds: $1.16B → $1.03B (-$127M)

17% less funds holding in top 10

Funds holding in top 10: 6 → 5 (-1)

Holders
134
Holders Change
+18
Holders Change %
+15.52%
% of All Funds
3.34%
Holding in Top 10
5
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-16.67%
% of All Funds
0.12%
New
37
Increased
64
Reduced
25
Closed
18
Calls
$14M
Puts
$9.27M
Net Calls
+$4.73M
Net Calls Change
-$850K

Top Buyers

Rank Fund Capital Flow
1
State Street
State Street
Massachusetts
+$43.6M
2
O
OrbiMed
New York
+$32.4M
3
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$29.3M
4
BlackRock
BlackRock
New York
+$23.4M
5
Citadel Advisors
Citadel Advisors
Florida
+$18.1M

Top Sellers

Rank Fund Capital Flow
1
WSC
White Square Capital
United Kingdom
-$53.6M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$10.9M
3
RG
Redmile Group
California
-$9.02M
4
YCMGA
York Capital Management Global Advisors
New York
-$4.24M
5
Voloridge Investment Management
Voloridge Investment Management
Florida
-$3.34M
Name Holding Trade Value Shares
Change 		Change in
Stake
TA
26
Teachers Advisors
New York
$7.03M +$3M +100,932 +65%
GPP
27
Great Point Partners
Connecticut
$6.99M -$1.33M -44,600 -15%
TCIM
28
TIAA CREF Investment Management
New York
$6.97M +$3.7M +124,439 +95%
JP Morgan Chase
29
JP Morgan Chase
New York
$6.45M +$341K +11,468 +5%
CC
30
Casdin Capital
New York
$5.88M +$3.38M +113,500 +112%
EAM
31
Eventide Asset Management
Massachusetts
$5.2M +$744K +25,000 +15%
Bank of New York Mellon
32
Bank of New York Mellon
New York
$5.04M +$1.33M +44,784 +32%
IHM
33
Iguana Healthcare Management
New York
$4.79M -$744K -25,000 -13%
DCM
34
Driehaus Capital Management
Illinois
$4.31M +$353K +11,879 +8%
RSCM
35
Rock Springs Capital Management
Maryland
$4.1M – – –
SFM
36
Sphera Funds Management
Israel
$4.1M +$4.46M +150,000 New
Charles Schwab
37
Charles Schwab
California
$4.09M +$1.16M +38,829 +35%
Wells Fargo
38
Wells Fargo
California
$3.89M +$640K +21,522 +18%
TCM
39
Tekla Capital Management
Massachusetts
$3.42M -$1.41M -47,500 -28%
HP
40
Harbourvest Partners
Massachusetts
$3.31M +$3.6M +120,878 New
Prudential Financial
41
Prudential Financial
New Jersey
$3.01M +$1.03M +34,749 +46%
CS
42
Credit Suisse
Switzerland
$3M +$553K +18,581 +20%
HLA
43
Hamilton Lane Advisors
Pennsylvania
$2.98M +$3.24M +108,786 New
AllianceBernstein
44
AllianceBernstein
Tennessee
$2.88M +$2.43M +81,500 +344%
AG
45
Artal Group
Luxembourg
$2.73M -$2.23M -75,000 -43%
Hudson Bay Capital Management
46
Hudson Bay Capital Management
Connecticut
$2.73M +$2.98M +100,000 New
ARTA
47
A.R.T. Advisors
New York
$2.73M +$2.49M +83,800 +523%
CLOS
48
Compagnie Lombard Odier SCmA
Switzerland
$2.71M +$1.03M +34,547 +54%
Barclays
49
Barclays
United Kingdom
$2.56M -$107K -3,604 -4%
EI
50
EAM Investors
California
$2.46M -$193K -6,475 -7%
1
2
3 4 5

GBT Hedge Fund Activity: Q2 2017 in Review

134 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Global Blood Therapeutics, Inc. (GBT) for Q2 2017, worth a combined $1.03B — down 11% from $1.16B a quarter earlier.

Buyers outnumbered sellers: 37 funds opened new GBT positions and 18 closed out — a net gain of 19 holders — while 64 added to existing stakes and 25 trimmed.

The largest buyer was State Street, adding an estimated $43.6M. The largest seller was White Square Capital, exiting entirely with an estimated $53.6M sold.

  • 134 institutional investors held Global Blood Therapeutics, Inc. (GBT) as of Q2 2017, up from 116 in Q1 2017.
  • Funds reported $1.03B of Global Blood Therapeutics, Inc. stock for Q2 2017, down 11% quarter-over-quarter.
  • 37 funds opened new Global Blood Therapeutics, Inc. positions in Q2 2017 and 18 closed out, a net change of +19 holders.
  • The largest Global Blood Therapeutics, Inc. buyer in Q2 2017 was State Street, an estimated $43.6M added.
  • The largest Global Blood Therapeutics, Inc. seller in Q2 2017 was White Square Capital, an estimated $53.6M sold.

Based on aggregated 13F filings for Q2 2017.